Indications:

Treatment of schizophrenia, treatment of acute mixed or manic episodes associated with bipolar I disorder.

Contraindications:

With the ingredients of the drug is contraindicated in patients with known hypersensitivity. Olanzapine is contraindicated in those with narrow angle glaucoma risk.

Adverse reactions:

Very frequently (> 10%): Weight gain, somnolence, Alzheimer’s disease who participated in studies where poor posture, plasma prolactin levels increased, but the clinical symptoms (eg, gynecomastia, galactorrhea and breast enlargement) rarely have been encountered.Although most patients to continue treatment were returned to normal levels. Frequently (1-10%): eosinophilia, increased appetite, glucose levels and triglyceride levels increased, dizziness , akathisia , orthostatic hypotension, constipation and dry mouth including the mild and transient in nature and anticholinergic effects, hepatic transaminases ( ALT , AST ), especially In the early treatment of asymptomatic transient elevations, asthenia , edema.. Infrequent% (0.1-1): hypotension, or syncope with or alone, bradycardia , sensitivity to light reaction, creatinine phosphokinase levels increased. Nadir (% 0.01-0.1): leukopenia, seizures (in this case the majority of seizures or seizures was to determine factors that increase susceptibility), rash. Very rare (<0.01%): thrombocytopenia, associated with ketoacidosis or coma can result in death, as some of hyperglycemia or worsening of diabetes, neuroleptic malignant syndrome, pancreatitis, hepatitis, priapism.

Interactions:

Olanzapine is metabolized by CYP1A2, the isoenzyme that induce or inhibit particular substances may affect the pharmacokinetics of olanzapine. Olanzapine metabolism, smoking and carbamazepine-induced whether olanzapine concentrations decrease may cause. Specific CYP1A2 inhibitor, fluvoxamine, olanzapine metabolism was significantly inhibited proved. Fluvoksamini following received olanzapine cmax'ındaki average increase in non-smokers among women 54% of smokers in men 77% were. Olanzapine The mean AUC increased, respectively, 52% and 108% respectively. fluvoxamine or ciprofloxacin, a CYP1A2 inhibitor ketoconazole such as the use of a lower starting dose of olanzapine should be considered. 50-60% activated charcoal reduces the bioavailability of oral olanzapine and olanzapine should be at least 2 hours before or after. Olanzapine may antagonize the effects of direct and indirect dopamine agonists. Observation of plasma levels of valproate as a therapeutic after the onset of treatment with olanzapine, valproate did not indicate the dose should be adjusted.

Warnings:

Seizures have been reported rarely in patients treated with olanzapine. Most of the reported seizures in the past or the risk factors for seizure occurrence were reported. . Signs and symptoms of tardive dyskinesia in patients receiving olanzapine revealed, the dose reduction or drug discontinuation should be considered.These symptoms can be temporarily increased or may increase even after cessation of treatment. Olanzapine in clinical trials for use in the elderly, postural hypotension was rarely seen. Di?er antipsikotiklerde oldu?u gibi, 65 ya??n üzerindeki hastalarda tansiyonun periyodik olarak ?lçülmesi ?nerilir. As with other antipsychotics, in patients over 65 years of age is recommended to measure blood pressure periodically. Congenital long QT syndrome, congestive heart failure, cardiac hypertrophy, hypokalemia, or the elderly hipomagnezemisi, known to increase the QTc interval should be careful when prescribing the drugs. Pregnancy category C.. On human experience is limited because of the potential risk to the fetus during pregnancy only if potential benefits in mind but should be used. Olanzapine in human milk is not known to pass through. Patients should be advised to avoid breastfeeding during their time olanzapine

Form:

Film Coated Tablets